JULPHAR Stock Overview
Manufactures and sells medicines, drugs, and other pharmaceutical, medical, cosmetic compounds in the United Arab Emirates, other GCC countries, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for JULPHAR from our risk checks.
Gulf Pharmaceutical Industries P.S.C. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.إ0.93 |
| 52 Week High | د.إ1.41 |
| 52 Week Low | د.إ0.70 |
| Beta | 0.26 |
| 1 Month Change | -3.22% |
| 3 Month Change | -11.14% |
| 1 Year Change | -0.21% |
| 3 Year Change | -37.80% |
| 5 Year Change | -66.60% |
| Change since IPO | -36.62% |
Recent News & Updates
Recent updates
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Jan 15
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking
Nov 04Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals
Mar 26Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.
Feb 08Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like
Dec 14Shareholder Returns
| JULPHAR | AE Pharmaceuticals | AE Market | |
|---|---|---|---|
| 7D | -3.0% | -0.3% | -0.8% |
| 1Y | -0.2% | 4.8% | -2.6% |
Return vs Industry: JULPHAR underperformed the AE Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: JULPHAR exceeded the AE Market which returned -2.6% over the past year.
Price Volatility
| JULPHAR volatility | |
|---|---|
| JULPHAR Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AE Market | 8.0% |
| 10% least volatile stocks in AE Market | 2.3% |
Stable Share Price: JULPHAR's share price has been volatile over the past 3 months.
Volatility Over Time: JULPHAR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | Basel Nimer Ziyadeh | www.julphar.net |
Gulf Pharmaceutical Industries P.S.C., together with its subsidiaries, manufactures and sells medicines, drugs, and other pharmaceutical, medical, cosmetic compounds in the United Arab Emirates, other GCC countries, and internationally. It operates through Manufacturing, Plant, Investment, and Others segment. The company provides generic medicines for pain management, GIT and endocrine, antiviral, respiratory, anti-infectives, cardio care, wound care, dermatology, CNS and psychiatry, biotechnology, gynecology women care, anemia, antibiotics, inflammation, and erectile dysfunction, as well as consumer care products, mouth wash, and vitamins and supplements.
Gulf Pharmaceutical Industries P.S.C. Fundamentals Summary
| JULPHAR fundamental statistics | |
|---|---|
| Market cap | د.إ1.08b |
| Earnings (TTM) | -د.إ98.00m |
| Revenue (TTM) | د.إ1.62b |
0.7x
P/S Ratio-11.0x
P/E RatioIs JULPHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JULPHAR income statement (TTM) | |
|---|---|
| Revenue | د.إ1.62b |
| Cost of Revenue | د.إ1.06b |
| Gross Profit | د.إ562.20m |
| Other Expenses | د.إ660.20m |
| Earnings | -د.إ98.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 34.64% |
| Net Profit Margin | -6.04% |
| Debt/Equity Ratio | 123.1% |
How did JULPHAR perform over the long term?
See historical performance and comparison